Lex

Elan's poison pill

Elan, the Irish drug company, is fending off a hostile bid by Royalty Pharma by buying royalties itself ‑ a $1bn investment in Theverance, a speciality respiratory drug company. Lex's Stuart Kirk and Vincent Boland discuss whether the strategy will work.